País: Canadá
Língua: inglês
Origem: Health Canada
ETIDRONATE DISODIUM
MYLAN PHARMACEUTICALS ULC
M05BA01
ETIDRONIC ACID
200MG
TABLET
ETIDRONATE DISODIUM 200MG
ORAL
60
Prescription
BONE RESORPTION INHIBITORS
Active ingredient group (AIG) number: 0113205002; AHFS:
CANCELLED POST MARKET
2017-01-09
PRODUCT MONOGRAPH PR MYLAN-ETIDRONATE Etidronate Disodium Tablets 200 mg Tablets USP BONE METABOLISM REGULATOR, ANTI-PAGETIC AGENT ANTI-HYPERCALCEMIC AGENT Mylan Pharmaceuticals ULC 85 Advance Road Toronto, Ontario M8Z 2S6 Date of Revision: September 8, 2011 Submission Control No: 148017 TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION......................................................... 1 SUMMARY PRODUCT INFORMATION ....................................................................... 1 INDICATIONS AND CLINICAL USE............................................................................. 1 CONTRAINDICATIONS .................................................................................................. 1 WARNINGS AND PRECAUTIONS................................................................................. 2 ADVERSE REACTIONS................................................................................................... 5 DRUG INTERACTIONS ................................................................................................... 7 DOSAGE AND ADMINISTRATION............................................................................... 7 OVERDOSAGE ................................................................................................................. 9 ACTION AND CLINICAL PHARMACOLOGY ............................................................. 9 STORAGE AND STABILITY......................................................................................... 10 DOSAGE FORMS, COMPOSITION AND PACKAGING ............................................ 10 PART II: SCIENTIFIC INFORMATION .............................................................................. 11 PHARMACEUTICAL INFORMATION......................................................................... 11 CLINICAL TRIALS......................................................................................................... 11 DETAILED PHARMACOLOGY....................................................................... Leia o documento completo